TEVIMBRA's Patent Gets FDA Time-Stamp Approval
Published Date: 2/26/2026
Notice
Summary
The FDA has officially set the review period for TEVIMBRA, a human biological product, which helps the company extend its patent protection. This means the patent clock can be paused, giving the maker more time to benefit from their invention. If anyone thinks the dates are wrong or wants to challenge the company’s effort during review, they must act by April 27 or August 25, 2026.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
FDA Sets TEVIMBRA Review Period
The FDA determined the regulatory review period for TEVIMBRA (tislelizumab-jsgr) is 2,997 days in total. That total includes a 2,021-day testing phase and a 976-day approval phase; key dates are: testing began December 31, 2015, the biologics license application was submitted July 12, 2021, and the application was approved March 13, 2024.
Applicant Seeks 1,987-Day Extension
The company applying for patent extension (BeiGene Switzerland GmbH) seeks 1,987 days of patent term extension for U.S. Patent No. 8,735,553 covering TEVIMBRA. The notice explains that this FDA determination establishes the maximum potential length, but the U.S. Patent and Trademark Office (USPTO) will apply statutory limitations when calculating the actual extension.
Deadlines To Challenge Dates and Due Diligence
Anyone who believes the published dates are incorrect may request a redetermination by April 27, 2026. Any interested person may petition FDA about whether the applicant acted with due diligence during the regulatory review period by August 25, 2026, following the petition requirements in 21 CFR 60.30.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-03850 — Determination of Regulatory Review Period for Purposes of Patent Extension; TRYNGOLZA
The FDA has officially set the review period for the drug TRYNGOLZA, which helps the company extend its patent protection. This means the drug maker could get extra time to keep their invention exclusive, potentially affecting competition and market prices. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by April 27 or August 25, 2026.
Next: 2026-03852 — Agency Information Collection Activity Under OMB Review: Intent To File a Claim for Compensation and/or Pension, or Survivors Pension and/or DIC
The VA is asking for public feedback on a form veterans use to say they plan to file for benefits like compensation or pension. This form helps set the start date for benefits, but no changes have been made to it—just more people are expected to use it. If you’re a veteran or survivor thinking about benefits, now’s the time to weigh in before March 30, 2026!
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in